Drug Database · Clinicians

Pilocarpine

Brands (2) Isopto Carpine, Piloptic-2Show all

US brand (reference label): Pilocarpine Hydrochloride; not a Philippine-registered brand.

Anti-glaucoma/Miotic; Antiglaucoma/Miotic; and others PH FDA category

Rx · Prescription drug3 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 53fa0b7a-f982-48a7-92c4-6f098683c1ed, version date May 19, 2020 (Pilocarpine Hydrochloride · Sandoz Inc). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • The reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
  • The management of acute angle-closure glaucoma.
  • The prevention of postoperative elevated IOP associated with laser surgery.
  • The induction of miosis.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Pilocarpine hydrochloride ophthalmic solution is indicated for the: Pilocarpine hydrochloride ophthalmic solution is a muscarinic cholinergic agonist indicated for:

  • The reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. (1.1)
  • The management of acute angle-closure glaucoma. (1.2)
  • The prevention of postoperative elevated IOP associated with laser surgery. (1.3)
  • The induction of miosis. (1.4) 1.1 Reduction of Elevated Intraocular Pressure (IOP) in Patients With Open-Angle Glaucoma or Ocular Hypertension. 1.2 Management of Acute Angle-Closure Glaucoma. 1.3 Prevention of Postoperative Elevated IOP Associated With Laser Surgery. 1.4 Induction of Miosis.

Contraindications

4 CONTRAINDICATIONS None. None. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

Instill one drop in the eye(s) up to four times daily. (2)

2.1 Reduction of Elevated IOP in Patients With Open-Angle Glaucoma or Ocular Hypertension

2.1 Reduction of Elevated IOP in Patients With Open-Angle Glaucoma or Ocular Hypertension One drop of pilocarpine hydrochloride ophthalmic solution 1%, 2%, or 4% should be applied topically in the eye(s) up to four times daily. Pilocarpine-naïve patients should be started on the 1% concentration as higher concentrations are often not tolerated initially.

The frequency of instillation and concentration of pilocarpine hydrochloride ophthalmic solution are determined by the severity of the elevated intraocular pressure and miotic response of the patient. To limit systemic exposure to pilocarpine, patients may be instructed to perform punctal occlusion for 2 minutes after instillation of pilocarpine hydrochloride ophthalmic solution.

2.2 Management of Acute Angle-Closure Glaucoma

2.2 Management of Acute Angle-Closure Glaucoma Prior to pilocarpine hydrochloride ophthalmic solution use, treatment with secretory suppressants and hyperosmotic agents may be needed to lower IOP below 50 mmHg and relieve iris ischemia. For initial management of acute angle-closure glaucoma, one drop of pilocarpine hydrochloride ophthalmic solution 1% or 2% may be applied topically in the eye(s) up to three times over a 30-minute period.

If laser iridoplasty or iridomy is used to break the attack, one drop of pilocarpine hydrochloride ophthalmic solution 4% should be administered prior to the procedure. Following laser iridoplasty, one drop of pilocarpine hydrochloride ophthalmic solution 1% should be administered four times daily until an iridotomy can be performed.

2.3 Prevention of Postoperative Elevated IOP Associated With Laser Surgery

2.3 Prevention of Postoperative Elevated IOP Associated With Laser Surgery One drop of pilocarpine hydrochloride ophthalmic solution 1%, 2%, or 4% (or two drops administered five minutes apart) should be applied topically in the eye(s) 15 to 60 minutes prior to surgery.

2.4 Induction of Miosis

2.4 Induction of Miosis One drop of pilocarpine hydrochloride ophthalmic solution 1%, 2%, or 4% (or two drops administered five minutes apart) should be applied topically in the eye(s).

2.5 Use With Other Topical Ophthalmic Medications

2.5 Use With Other Topical Ophthalmic Medications Pilocarpine hydrochloride ophthalmic solution may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.

2.6 Use in Pediatric Patients

2.6 Use in Pediatric Patients In children under 2 years of age, one drop of pilocarpine hydrochloride ophthalmic solution 1% should be applied topically in the eye(s) three times daily. Children 2 years of age and over should be dosed as for adults. For the induction of miosis prior to goniotomy or trabeculotomy in children, one drop of pilocarpine hydrochloride ophthalmic solution 1% or 2% should be applied topically in the eye 15 to 60 minutes prior to surgery.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of pilocarpine hydrochloride ophthalmic solution in pediatric patients have been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Dosage forms

Philippines

  • Ophthalmic solution: 20 mg/mL
  • Sterile ophthalmic solution: 20 mg/mL
  • Sterile opthalmic solution drops: 20 mg/mL

Registered products in the Philippines

3 products registered with the Food and Drug Administration (FDA) Philippines list Pilocarpine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products3
Philippine FDA-registered products for Pilocarpine
Package insert
Isopto CarpinePilocarpine Hydrochloride
20 mg/mL (2% w/v) Sterile Ophthalmic SolutionPlastic Bottle x 15 mL (Box of 1's)
Rx
Alcon-Couvreur NVBelgium
Novartis Healthcare Philippines, Inc.
DR-XY12411
Feb 16, 2027
NonePilocarpine Nitrate
20mg/ml (2% w/v) Ophthalmic Solution (eye drops)White Opaque Plastic Dropper Bottle x 5ml
Rx
AurolabIndia
Brady Pharma Inc.
DRP-4441
Oct 10, 2027
Piloptic-2Pilocarpine Hydrochloride
20 mg/mL ( 2% w/v) Sterile Opthalmic Solution DropsLDPE Clear Plastic Tip Bottle with HDPE Blue Cap x 10 mL (Box of 1’s)
Rx
Laboratorios Ashford LDAChina
Marrion Pharma Inc.
DR-XY35268
Feb 9, 2037

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Bottle filled with 15 mL of 1% (10 mg/mL), 2% (20 mg/mL), or 4% (40 mg/mL) pilocarpine hydrochloride sterile ophthalmic solution. • Solution containing 1% (10 mg/mL), 2% (20 mg/mL) or 4% (40 mg/mL) pilocarpine hydrochloride. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • • Poor Illumination: Exercise caution in night driving and other hazardous occupations in poor illumination. (5.1)
  • • Preexisting Retinal Disease: Rare cases of retinal detachment have been reported; a thorough examination of the retina, including funduscopy is advised in all patients prior to the initiation of therapy. (5.2)
  • • Iritis: Caution is advised in patients with iritis. (5.3)
  • • Congenital Glaucoma: Caution is advised in pediatric patients with primary congenital glaucoma for control of IOP as cases of a paradoxical increase in IOP have been reported. (5.4)
5.1 Poor Illumination

5.1 Poor Illumination Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear.

5.2 Preexisting Retinal Disease

5.2 Preexisting Retinal Disease As with all miotics, rare cases of retinal detachment have been reported when used in certain susceptible individuals and those with preexisting retinal disease; therefore, a thorough examination of the retina including funduscopy is advised in all patients prior to the initiation of therapy.

5.3 Iritis

5.3 Iritis Pilocarpine hydrochloride ophthalmic solution is not recommended to be used when iritis is present.

5.4 Primary Congenital Glaucoma

5.4 Primary Congenital Glaucoma Caution is advised when using pilocarpine hydrochloride ophthalmic solution in pediatric patients with primary congenital glaucoma for control of IOP as cases of a paradoxical increase in IOP have been reported. In addition, the use of pilocarpine hydrochloride ophthalmic solution is not recommended in pediatric patients diagnosed with glaucoma secondary to anterior segment dysgenesis or uveitis (especially if uveitis is active).

5.5 Contact Lens Wear

5.5 Contact Lens Wear Contact lens wearers should be advised to remove their lenses prior to the instillation of pilocarpine hydrochloride ophthalmic solution and to wait 10 minutes after dosing before reinserting their contact lenses.

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS Most common adverse reactions are headache/browache, accommodative change, eye irritation, eye pain, blurred vision, and/or visual impairment. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described below reflect exposure in four controlled clinical trials of 90 days to 2 years duration in 317 patients diagnosed with open-angle glaucoma or ocular hypertension. In the four clinical trials, patients were treated with pilocarpine hydrochloride ophthalmic solution 2%, two to four times daily or with pilocarpine 1%, 1.75%, or 2% in fixed combination with betaxolol 0.25%, two or three times daily.

The most frequently reported adverse reactions occurring in ≥ 5% of patients in the pilocarpine 2% populations were: headache/brow ache, accommodative change, blurred vision, eye irritation, visual impairment (dim, dark, or “jumping” vision), and eye pain. The adverse reaction profile reported for the use of pilocarpine hydrochloride ophthalmic solution in pediatric patients is comparable to that seen in adult patients.

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Animal reproduction studies have not been conducted with pilocarpine hydrochloride. It is also not known whether pilocarpine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Pilocarpine hydrochloride ophthalmic solution should be given to a pregnant woman only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

8.3 Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when pilocarpine hydrochloride ophthalmic solution is administered to a nursing woman.

Mechanism of action

12.1 Mechanism of Action Pilocarpine hydrochloride is a direct acting cholinergic parasympathomimetic agent which acts through direct stimulation of muscarinic receptors and smooth muscle such as the iris and secretory glands. Pilocarpine contracts the ciliary muscle, causing increased tension on the scleral spur and opening of the trabecular meshwork spaces to facilitate outflow of aqueous humor.

Outflow resistance is reduced, lowering IOP. Pilocarpine also produces miosis through contraction of the iris sphincter muscle. Miosis relieves appositional angle narrowing and closure, which lowers IOP in certain types of angle-closure glaucoma.

US FDA label

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Systemic exposure to pilocarpine was evaluated in 14 healthy subjects administered 2 drops of pilocarpine hydrochloride ophthalmic solution 4% to both eyes four times daily for eight days. A comparison of C max values on Days 5 and 8 indicated that pilocarpine concentrations in plasma reached steady-state following topical administration of pilocarpine hydrochloride ophthalmic solution 4%. The mean (SD) C max and AUC 0-last values on Day 8 were 3.7 (3.2) ng/mL and 7.7 (8.4) ng×hour/mL, respectively. The T max values on Day 8 ranged from 0.5 to 1 hour.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Pilocarpine 2%, 15 mL Bottle₱250.00–₱270.18Reference ₱250.00per bottleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Pilocarpine (as hydrochloride)
PNF listingEye Drops Solution: 1%, 10 mL and 15 mL bottle
PNF listingEye Drops Solution: 2%, 10 mL and 15 mL bottle
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Pilocarpine Hydrochloride · Sandoz Inc [US FDA-approved label, version 8, May 19, 2020]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53fa0b7a-f982-48a7-92c4-6f098683c1ed
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .